I just read a headline that might just be the most perfect definition of irony I've ever seen. Remember our ignorant friend who claimed OCR-002 had a weak patent? He recommended investors short OCRX and buy HPTX because Ravicti was going to be a big player in the HE market. Well, get ready to cheer...Par pharma just filed a paragraph 4 against HPTX claiming the patent for Ravicti is invalid due to methods of construction.If his article wwasn't already pathetic enough he may go down in history as the biggest buffoon on the planet. Karma!!
Nice find biocourseinc,It seems our buddy “PAUL” has a little different opinion then the investor at the Ocera camp. I think he just tried to shack the tree a little to see what or who he could get to fallout.
Did I miss something? Were we not supposed to sell all out Ocera shares and buy Hyperion Therapeutics?
Sorry Mr. Reed I guess that you are not very convincing.